2,468 Shares in Novo Nordisk A/S (NYSE:NVO) Acquired by Lockerman Financial Group Inc.

Lockerman Financial Group Inc. purchased a new position in Novo Nordisk A/S (NYSE:NVO) during the 1st quarter, HoldingsChannel reports. The institutional investor purchased 2,468 shares of the company’s stock, valued at approximately $317,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of NVO. Pacific Center for Financial Services increased its holdings in Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the period. First PREMIER Bank acquired a new stake in shares of Novo Nordisk A/S during the 1st quarter worth approximately $25,000. CNB Bank acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter worth approximately $26,000. Tyler Stone Wealth Management grew its stake in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock worth $27,000 after purchasing an additional 146 shares during the period. Finally, West Paces Advisors Inc. grew its stake in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock worth $27,000 after purchasing an additional 150 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on NVO. Argus lifted their price target on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, June 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday, June 17th. BMO Capital Markets reissued an “outperform” rating and issued a $163.00 price target on shares of Novo Nordisk A/S in a research note on Tuesday. Finally, The Goldman Sachs Group assumed coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price target on the stock. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus target price of $145.67.

Novo Nordisk A/S Trading Up 0.1 %

Shares of NYSE NVO traded up $0.17 during trading on Friday, hitting $144.66. 189,222 shares of the company were exchanged, compared to its average volume of 4,427,803. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $148.15. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. The company has a fifty day moving average price of $134.16 and a 200-day moving average price of $122.88. The firm has a market capitalization of $649.17 billion, a PE ratio of 49.83, a P/E/G ratio of 1.43 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, topping the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The business had revenue of $9.52 billion for the quarter, compared to analyst estimates of $9.23 billion. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.41 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.